Marinus Pharmaceuticals

^{Priced, Nasdaq: MRNS}

Early-stage biotech developing an add-on therapy for epilepsy.

Industry: Health Care

First Day Return: 0.0%

MRNS

Early-stage biotech developing an add-on therapy for epilepsy.

IPO News for Marinus Pharmaceuticals

Epilepsy device maker NeuroSigma sets terms for $50 million IPO 09/29/14
Epilepsy device maker NeuroSigma files for a $50 million IPO 08/26/14
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price 08/01/14

IPO Data
IPO Date	07/31/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$45
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.marinuspharma.com
Headquarters	New Haven, CT, United States
Founded	2003
Employees at IPO	4

IPO News for Marinus Pharmaceuticals

Marinus Pharmaceuticals (MRNS) Performance